Coherus Oncology (CHRS) Non-Current Debt (2016 - 2026)

Coherus Oncology (CHRS) has 11 years of Non-Current Debt data on file, last reported at $37.1 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt rose 1.0% year-over-year to $37.1 million; the trailing twelve-month figure through Mar 2026 stood at $37.1 million (up 1.0% YoY), and the FY2025 full-year result was $37.1 million, up 0.96% from the prior year.
• Non-Current Debt steadied at $37.1 million in Q1 2026, from $37.1 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $246.5 million in Q4 2023 to a low of $36.5 million in Q2 2024.
• A 5-year average of $131.4 million and a median of $72.5 million in 2024 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt jumped 323.39% in 2022 and slumped 85.14% in 2024, its largest moves.
• Tracing CHRS's Non-Current Debt over 5 years: stood at $245.5 million in 2022, then grew by 0.41% to $246.5 million in 2023, then sank by 85.11% to $36.7 million in 2024, then rose by 0.96% to $37.1 million in 2025, then grew by 0.26% to $37.1 million in 2026.
• Business Quant data shows CHRS's Non-Current Debt at $37.1 million in Q1 2026, $37.1 million in Q4 2025, and $37.0 million in Q3 2025.